In a study of 104 treatment-naïve patients with de novo EGFR positive and MET over-expressed advanced NSCLC, EGFR TKI monotherapy (n = 48), EGFR TKI plus crizotinib (n = 9), EGFR TKI plus chemotherapy (n = 12), and chemotherapy alone (n = 35) were compared. Here, EGFR is linked to non-small cell lung carcinoma.